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Abstract 
Periodontitis is a chronic inflammatory disease resulting in the destruction of the tissue and 
alveolar bone supporting the teeth and leading ultimately to tooth loss. Prostaglandin E2 
(PGE2) is an important inflammatory mediator in the pathogenesis of periodontitis. The 
biosynthesis of PGE2 is catalysed by three groups of enzymes acting sequentially: 
phospholipase A2 (PLA2), cyclooxygenases (COX-1 and COX-2) and prostaglandin E 
(PGE) synthases, which catalyse the final step of PGE2 synthesis. Three PGE synthase 
isoforms have been identified: i) the inducible microsomal membrane-associated and 
glutathione-dependent PGE synthase, mPGES-1, ii) the constitutively expressed cytosolic 
PGE synthase, cPGES, and iii) the glutathione-independent, membrane-associated 
mPGES-2. The aim of this thesis was to investigate the expression of PGE synthases in 
gingival tissue from periodontitis patients, as well as to study their expression and 
regulation in relation to PGE2 production in gingival fibroblasts.  
In periodontitis-affected gingival tissue, we demonstrated in vivo protein expression of 
mPGES-1, mPGES-2 and cPGES, as well as COX-2 in fibroblasts, endothelial cells, 
smooth muscle cells, epithelial cells and immune cells. We further showed that, in cell 
cultures of gingival fibroblasts and smooth muscle cells, the inflammatory cytokines 
tumour necrosis factor α (TNFα) and interleukin-1β (IL-1β), or co-culture with 
lymphocytes, markedly induced mPGES-1 and COX-2 expression, accompanied by an 
increase in PGE2 production. In cultured endothelial cells, only TNFα was found to 
increase PGE2 production, via enhanced COX-2 expression. In mast cell cultures, basal 
levels of PGE2 were detected, but no increase was observed in response to TNFα or IL-1β.  
To elucidate the impact of mPGES-1 inhibition on mPGES-2 and cPGES expression, 
as well as on PGE2 production we used knock-down of mPGES-1 expression by small 
interfering RNA (siRNA). The cytokine-induced protein expression of mPGES-1 was 
reduced by up to 79% by siRNA silencing, without affecting mPGES-2 or cPGES 
expression. Moreover, mPGES-1 siRNA did not affect the cytokine-stimulated PGE2 
production, whereas levels of the downstream prostaglandin F2α (PGF2α) were enhanced.  
Using inhibitors and activators of various signalling pathways, we demonstrated that 
cytokine-induced mPGES-1 expression in gingival fibroblasts did not involve protein 
kinase C, p38 mitogen-activated protein kinase or tyrosine kinase pathways, in contrast to 
COX-2 expression. We further observed a possible positive feedback loop in which PGE2 
and PGF2α increased the expression of mPGES-1. Furthermore, cytokine-induced 
mPGES-1 expression and PGE2 production were reduced after the inhibition of the 
upstream enzyme PLA2 and increased after the addition of arachidonic acid, the product of 
PLA2. The proposed anti-inflammatory prostaglandin 15-deoxy-∆12,14-prostaglandin J2 
(15d-PGJ2), reduced mPGES-1 expression but not COX-2 expression or PGE2 
production. 
To further explore the pathways involved in increased PGE2 synthesis in TNFα-
stimulated gingival fibroblasts, a global gene expression profile was established using a 
microarray platform. Enrichment analysis of the gene expression data led to further 
investigation of nuclear factor-κB (NF-κB) and c-Jun N-terminal kinase (JNK) signalling 
pathways, revealing that these pathways are involved in the signal transduction of TNFα-
induced mPGES-1 and COX-2 expression. 
In conclusion, all three PGE synthases are expressed in gingival tissue from patients 
with periodontitis. The isoenzyme mPGES-1 is the main PGE synthase involved in 
  
cytokine-induced PGE2 production in gingival fibroblasts. The cytokine-increased 
expression of mPGES-1 involves the signal pathways JNK and NF-κB. Furthermore, the 
prostaglandins PGE2 and PGF2α increase mPGES-1 expression, which may create a 
positive feedback loop. Collectively, these results suggest that inflammation-induced 
production of PGE2 by gingival fibroblasts, mediated by the increased expression of 
mPGES-1 and COX-2, may contribute to chronic inflammation in periodontitis. The 
results provide new insights into the expression and regulation of mPGES-1 in gingival 
fibroblasts and gingival tissue. 
 
Keywords: c-Jun N-terminal kinase, cyclooxygenase, cytokines, gingival fibroblasts, 
gingival tissue, inflammation, interleukin-1β, nuclear factor-κB, mPGES-1, periodontitis, 
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he process of inflammation is vital for our survival. Without inflammation, 
wounds and infections would never heal and we would become helpless victims of 
our environment. However, inflammation can also work to our disadvantage. 
After an acute phase of inflammation in response to a bacterial infection, for example, the 
inflammation is generally resolved and healing can begin. When the inflammation is not 
resolved, we are instead left with an ongoing, chronic inflammation. In chronic 
inflammation, tissue destruction and healing are usually present at the same time, but the 
balance is delicate and can tilt towards destruction. Chronic inflammation is involved in 
many diseases, including rheumatoid arthritis, cardiovascular disease, cancer, type 2 
diabetes mellitus and periodontitis. This work will focus on periodontitis, with special 
emphasis on prostaglandin E2, but the elucidation of the molecular mechanisms behind the 
pathogenesis of periodontitis might one day lead to a new treatment strategy not only for 
periodontitis but also for other chronic inflammatory conditions.  
 
 
T 
   3 
Pathogenesis of periodontitis 
Periodontal disease, ranging from gingivitis to periodontitis, has probably been a factor of 
human life since prehistoric times.1 Even Egyptian mummies from a thousand years BC 
have been shown to exhibit possible signs of periodontitis.2 Today, periodontal disease is 
common and around 5-15% of the population suffer from severe periodontitis.3,4 
Periodontitis is not a life-threatening condition. Nevertheless, the loss of the bone 
supporting the tooth is irreversible and, furthermore, it has been suggested that there are 
associations between periodontal disease and systemic conditions such as heart disease, 
obesity and rheumatoid arthritis.5-7  
 
Periodontitis is a chronic inflammatory state of the gingiva causing destruction of the 
gingival tissue, as well as the alveolar bone, resulting in reduced support for the teeth and 
ultimately tooth loss (Figure 1).8-10 The definition of periodontitis is based on a number of 
clinical criteria, including bleeding on probing, pocket depth and clinical attachment loss.11 
However, the specific use of these criteria varies substantially between different studies.11 
The pathogenesis of periodontitis was gradually elucidated during the later half of the 20th 
century. In the 1960s and 1970s, research on humans and animals showed that bacteria 
play a critical role in initiating gingivitis and periodontitis.12-14 Leading up to the 1980s, 
there were further advances within the field and the pivotal role of the host inflammatory 
response in disease progression began to emerge.15-17 The importance of hereditary factors 
was subsequently demonstrated in several studies, including those comparing monozygotic 
and dizygotic twins.18,19 Furthermore, systemic conditions and environmental factors such 
as smoking were also shown greatly to affect disease onset and progress.20-22 Since over a 
decade, the concept of periodontitis pathogenesis has been considered to be a complex 
interaction between the microbial challenge, host response and environmental and genetic 
risk factors (Figure 2).20 To summarise, bacterial components of the biofilm initiate an 
inflammatory cascade, including the infiltration of immune cells and the production of 
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inflammatory mediators in the periodontal tissue, which results in soft tissue disintegration 
and bone destruction. This process will be discussed in more detail in the following 
sections.  
 
Bacterial challenge 
Bacterial components, such as lipopolysaccharides (LPS), peptidoglycans and lipotechoic 
acids, that instigate the inflammatory reaction can be found in the biofilm on the tooth 
surface.21,22 The biofilm starts to form when bacteria adhere to the surface of salivary 
proteins naturally covering the tooth.23 The presence of bacteria on the surface then 
facilitates the adhesion of other bacteria and an extracellular matrix containing complex 
carbohydrates is eventually secreted.23 This matrix makes the biofilm more resistant to 
physical removal, by toothbrushing, for example.23 The different bacteria of the biofilm can 
compete, using antimicrobial peptides, but they can also form symbiotic relationships that 
promote mutualistic growth.23 The general presence of bacteria in the oral cavity is not 
harmful per se and a microflora containing several hundred species can be found in dental 
plaque without the presence of periodontitis. As periodontitis develops, however, the 
composition of the microflora shifts away from beneficial species and towards species 
associated with periodontal disease.24 The current literature points to particular pathogens 
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commonly associated with disease, including Porphyromonas gingivalis, Tannerella forsythia 
and Treponema denticola.25,26  
The physical removal of bacterial plaque and calculus is currently the main approach to 
treating periodontitis. Together with root planing and scaling, locally or systemically 
administered antibiotics have also been suggested to have a beneficial effect on treatment 
outcome.27,28 A different approach, which is still not feasible for common practice but is 
possible in principle, is to utilise a vaccine against specific detrimental bacterial species such 
as P. gingivalis.29 It has also been suggested that beneficial bacteria might be administered 
as probiotics to shift the balance towards a healthy microflora as a treatment for 
periodontitis.30 However, treatment strategies for periodontitis need not be limited to 
bacterial intervention. An in-depth understanding of the host response could potentially 
reveal targets for additional therapies that may ameliorate disease progress. 
 
Host immuno-inflammatory response 
The host response to the bacterial challenge includes the action and stimulation of different 
inflammatory cell types, as well as resident cells of the tissue (Figure 3).20,31-33 Bacterial 
antigens, such as LPS and peptidoglycans, are recognised by toll-like receptors on the 
surface of host cells, which initiates an inflammatory response.34 Through a cascade of 
events, mast cells are stimulated to release vasoactive amines and pre-formed tumour 
necrosis factor α (TNFα), contributing to increased vascular permeability, as well as the 
increased expression of adhesion molecules, such as intercellular adhesion molecule-1 
(ICAM-1) and P-selectin, on endothelial cell surfaces.21,33 This process recruits 
polymorphonuclear leukocytes (PMNs) into the tissue, which then release lysosomal 
enzymes, contributing to tissue degradation.33 Lymphocytes, mainly including T-cells, and 
macrophages further invade the tissue. At this point, 60-70% of the collagen in the 
gingival connective tissue is degraded at the site of the lesion, but the bone is still intact.15,33 
At this stage, it is still possible for the gingival tissues to repair and remodel without 
permanent damage. However, the inflammation may change character to a B-cell/plasma 
cell response, with subsequent connective tissue breakdown and irreversible bone loss.33 In 
this scenario, macrophages form pre-osteoclasts which then mature into osteoclasts, capable 
of degrading the alveolar bone.35  
In addition to the invading inflammatory cells, which produce inflammatory mediators 
and drive the process of inflammation, the resident cells of the gingival tissue may also 
affect the progression of periodontitis. The vessels, consisting of endothelial cells and 
smooth muscle cells, are the first to come in contact with circulatory inflammatory cells 
invading the tissue. In response to TNFα, endothelial cells express the surface adhesion 
molecules which attract the inflammatory cells to the site of inflammation.21,33 In gingival 
connective tissue, the most ubiquitous resident cells are gingival fibroblasts. By producing 
inflammatory mediators, such as cytokines, chemokines, proteolytic enzymes and 
prostaglandins, these cells participate in the inflammatory response and contribute to 
disease persistence.36-40 The periodontal ligament fibroblasts that are located between the 
tooth and the alveolar bone are also involved in the inflammatory reaction, producing 
inflammatory mediators, such as prostaglandins, proteolytic enzymes and factors affecting 
bone resorption.41-43 
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Inflammatory mediators 
Throughout each step of the process of inflammation, pro-inflammatory mediators are 
released and affect different cell types to propel the inflammatory cascade. These mediators 
include pro-inflammatory cytokines and chemokines, proteolytic enzymes and 
prostaglandins.  
Several pro-inflammatory cytokines are involved in the pathogenesis of periodontitis, 
including the prominent TNFα, interleukin-1 (IL-1) and interleukin-6 (IL-6). The 
cytokines IL-1 and IL-6 are abundantly produced in the B-cell/plasma cell response which 
characterises the progression of periodontitis.33 IL-6 is produced by epithelial cells, 
lymphocytes, monocytes and fibroblasts in response to bacterial LPS, IL-1 and TNFα and 
has been shown to stimulate the formation of osteoclasts in vitro.21,44 Increased levels of IL-
6 have been demonstrated in the gingival crevicular fluid (GCF) of patients with 
periodontitis, compared with healthy controls, and higher expression of IL-6 was reported 
in diseased gingival tissues when compared with healthy ones in periodontitis patients.45,46 
The inflammatory cytokines IL-1 and TNFα play an especially central role in the 
pathogenesis of periodontitis47 and are used in our in vitro model of inflammation 
throughout this thesis. As mentioned above, TNFα is involved from early on in the 
inflammatory cascade, as it is released from mast cells in response to bacterial challenge. In 
the clinical context, TNFα and IL-1β have been found in increased concentrations in the 
GCF and gingival tissue of periodontitis sites.48-50 The pivotal role of these cytokines in 
periodontitis is further supported by reports that attachment loss is reduced in 
periodontitis patients with rheumatoid arthritis after anti-TNF treatment and that the 
administration of recombinant TNFα or IL-1 to the gingiva has been shown to exacerbate 
experimental periodontitis in rats.51-53 In addition, soluble receptors of IL-1 and TNF have 
been shown greatly to inhibit the progress of periodontitis in a primate model.54,55 At 
cellular level, these two cytokines are involved in the induction of several other 
inflammatory mediators, such as IL-6, IL-8, matrix metalloproteinases (MMPs) and 
prostaglandin E2.8,21,56-58 TNFα and IL-1 are produced by many cell types in periodontal 
tissue: monocytes/macrophages, PMN cells, fibroblasts, epithelial cells, endothelial cells 
and osteoblasts.47 To summarise, these two cytokines occupy a spider-in-the-web position 
among mediators of the inflammatory cascade in periodontitis. 
Chemokines are cytokines involved in inducing chemotaxis in responsive cells. The 
chemokines IL-8 and monocyte chemoattractant protein-1 (MCP-1) attract neutrophils 
and other leukocytes to the site of inflammation. IL-8 is secreted by many different cells, 
including monocytes, lymphocytes, epithelial cells, endothelial cells and fibroblasts, in 
response to IL-1, TNFα and LPS.8,59 High levels of IL-8 expression have been shown to be 
localised to sites with high concentrations of PMN cells in gingival tissue from patients 
with periodontitis.60 Furthermore, increased levels of IL-8 have been demonstrated in GCF 
from periodontitis sites compared to healthy control sites and the levels of IL-8 decreased 
after periodontal therapy.61 The chemokine MCP-1 is produced by endothelial cells, 
epithelial cells and fibroblasts in response to bacterial components, such as LPS, or 
inflammatory mediators.21,62 The involvement of MCP-1 in periodontitis is supported by 
studies demonstrating increased levels of the chemokine in gingival biopsies and GCF from 
patients with periodontitis, as well as decreased MCP-1 in GCF after the treatment of 
periodontitis.49,63,64 
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The proteolytic MMP enzymes and their endogenous inhibitors, termed tissue 
inhibitors of metalloproteinases, are involved in the homeostasis of the extracellular matrix 
in healthy tissue, but they are also key players in the process of inflammation and tissue 
degradation. In periodontitis, TNFα and IL-1β stimulate fibroblasts to secrete an excess of 
MMPs that degrade the extracellular matrix.21 MMP-8, one of the several MMPs involved 
in periodontitis, has been observed in increased levels in periodontitis, as well as in 
subsequently reduced levels after treatment.65  
Among prostaglandins, prostaglandin E2 (PGE2) is the most prominent in the 
pathogenesis of periodontitis.66,67 PGE2 is produced by immune cells as well as fibroblasts 
and other resident cells of the gingival tissue, and has a wide range of biological effects on 
the cells of the diseased gingiva.36,66 The effects of PGE2 include the stimulation of 
inflammatory mediators and MMPs, as well as osteoclast formation through the receptor 
activator of nuclear factor-κB ligand (RANKL).66,68 Prostaglandins, especially PGE2, are 
central to the work in this thesis and will therefore be discussed in detail in the following 
chapters.  
 
The multitude of inflammatory processes involved in the host response provides an equal 
multitude of possible targets for therapeutic intervention. Modulation of the host response 
is a possible treatment strategy for periodontitis, in conjunction with the physical removal 
of the microbial challenge. Patients with periodontitis who are treated with non-steroidal 
anti-inflammatory drugs (NSAIDs) have shown reduced periodontal disease progression 
and reduced alveolar bone resorption.69,70 However, a cross-sectional study by Heasman 
and Seymour71 demonstrated no differences in alveolar bone loss or other clinical 
parameters when comparing patients on long-term NSAID therapy with controls not 
treated with NSAIDs. It has also been shown that the antibacterial substance triclosan, 
which is used in toothpastes, has anti-inflammatory effects and enhances the healing 
response in chronic periodontitis patients.72-74 Interestingly, triclosan has been shown to 
reduce the levels of PGE2, suggesting that the anti-inflammatory effect of triclosan may be 
partly mediated by decreased PGE2 levels.75,76 The following chapters in this thesis are 
dedicated to prostaglandins and to PGE2 in particular.  
 
Prostaglandins 
The Nobel Prize in Physiology or Medicine in 1982 was awarded jointly to Sune K. 
Bergström, Bengt I. Samuelsson and John R. Vane “for their discoveries concerning 
prostaglandins and related biologically active substances”. However, the story of 
prostaglandins began much earlier. About a century ago, it was discovered that the urinary 
bladder and blood pressure of dogs was affected by an extract from the human prostate 
gland.77 In 1930, Kurzrok and Lieb showed that human semen caused contraction of the 
uterus.78 These and other findings subsequently led to the discovery of substances in 
human seminal plasma that had substantial biological effects. The name “prostaglandin” 
refers to the origin of the substances, which was seemingly the prostate gland.79 In 1960, 
the Swedish researchers Sune K. Bergström and Jan Sjövall published their isolation of two 
separate substances from sheep seminal vesicles.80,81 These two compounds were named 
after the respective solvent in which they were soluble; prostaglandin E for ether and 
prostaglandin F for phosphate buffer, fosfatbuffert in Swedish. The structures of these 
prostaglandins were subsequently elucidated by Bergström and his graduate student Bengt 
I. Samuelsson.82  
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Today, several different prostaglandins have been characterised. Almost all organs can be 
affected by prostaglandins and they can be produced by most of the cells of the human 
body. Their action is autocrine or paracrine, which means that the signalling of 
prostaglandins is localised to the immediate surroundings of the site of synthesis. They are 
not stored in the cell but are synthesised de novo as a result of cell activation by cytokines, 
growth factors or other stimuli. The biosynthesis of all prostanoids (prostaglandins, 
prostacyclins and thromboxanes) begins with the conversion of membrane phospholipids 
to arachidonic acid (AA), which can then be further metabolised by a range of enzymes to 
form different prostaglandins. AA can also be converted into leukotrienes, which are 
produced mainly in inflammatory cells and are involved in allergic reactions, as well as in 
sustaining inflammatory reactions.83,84 An overview of prostanoid biosynthesis is given in 
Figure 4.  
Prostaglandins are secreted from the cell through the plasma membrane by a 
prostaglandin transporter protein.85 The actions of prostaglandins on target cells are then 
dependent on the prostaglandin receptors on their surfaces. Currently, nine prostaglandin 
receptors have been characterised, not counting splice variants that differ only slightly from 
one another.86 These receptors include the four receptors EP1-EP4 for PGE2, DP1 and DP2 
for PGD2, as well as IP, FP and TP for PGI2, PGF2α and TXA2 respectively.84 The 
prostaglandin receptors are G-protein-coupled receptors (GPCRs), apart from DP2, which 
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is grouped with the chemoattractant receptors. Most of the prostaglandin GPCRs are 
found in the plasma membrane, but receptors can also be localised to the nuclear 
envelope.87,88 Examples of the many diverse actions of different prostaglandins on target 
cells throughout the human body are illustrated in Figure 5 which is adapted from Funk 
2001.84 The single prostaglandin that has merited the largest number of research 
publications to date is PGE2. It has been implicated in such diverse processes as 
rheumatoid arthritis,89-91 periodontitis,92,93 atherosclerosis,94,95 embryonic development,96 
hyperalgesia,97 chronic constipation98 and skin tumour progression.99 Regarding 
periodontitis, concentrations of PGE2 are enhanced in periodontal tissue and GCF of 
periodontitis patients, compared with periodontally healthy controls.92,93 Moreover, the 
enhanced levels of PGE2 in periodontitis correlate well with disease severity as measured by 
attachment loss.100  
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Prostaglandin E2 
Prostaglandin E2 is involved in many different biological processes throughout the human 
body. In vivo, PGE2 has a half-life of less than one minute.101 It is generally degraded in 
several steps to dicarboxylic acids, which are excreted into the urine, but can also be 
reduced by PGE 9-ketoreductase to form PGF2α.102,103 The short in vivo half-life of PGE2 is 
consistent with its autocrine or paracrine action on the cells of the tissue. The effect of 
PGE2 on a specific cell type depends on the prostaglandin receptors, EP1 through EP4. The 
receptors EP1 and EP3 are expressed by neurons, among other cells, and cause fever and 
pain response; EP1 through enhanced intracellular Ca2+ levels and EP3 through the 
inhibition of adenylate cyclase.84,104 EP2 and EP4, which are reported to activate adenylate 
cyclase and protein kinase A signalling, are more relevant to the pathogenesis of 
periodontitis.105 In rodent models, these two receptors have been shown to be involved in 
bone resorption in response to PGE2.106,107 The major pathway by which PGE2 stimulates 
bone resorption is generally considered to be via the up-regulation of RANKL expression 
and the inhibition of osteoprotegerin (OPG) expression in osteoblastic cells.105 OPG acts as 
a decoy receptor for RANKL and the inhibition of its expression enables RANKL to 
interact with its receptor RANK on other cells. RANKL then binds to RANK on osteoclast 
lineage cells to drive differentiation to osteoclasts,35,105 as schematically illustrated in Figure 
6 (adapted from Blackwell et al. 2010105). In osteoclastogenesis, the stimulatory effect of 
oral pathogen sonicates has been demonstrated to be primarily mediated through the 
PGE2/RANKL pathway in primary mouse osteoblasts co-cultured with bone marrow 
cells.108 It has also been reported that RANKL-stimulated osteoclastogenesis can be 
enhanced by PGE2 and LPS through direct effects on the hematopoietic cell lineage.68 
PGE2 has been shown both to inhibit and stimulate OPG expression,43,109 a contradiction 
which may be the result of differing incubation times, as has been suggested for the effect 
of PGE2 on osteoclast formation.105 Inflammatory cytokines such as IL-1β induce RANKL 
and/or OPG expression in several cell types, including osteoblasts, gingival fibroblasts and 
periodontal ligament fibroblasts.43,110  
In addition to its effect on bone resorption, PGE2 can also stimulate bone formation in 
cell cultures, as well as in vivo.105,111-113 Interestingly, intermittent PGE2 administration has 
been shown to lead to bone formation in rats, whereas continuous administration 
promotes bone resorption.114 However, the mechanisms behind the balance between bone 
formation and resorption with regard to PGE2 are still largely unresolved and may depend 
on the cellular environment.105  
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Levels of PGE2 can be modulated by regulation of the enzymes involved in its synthesis. In 
the light of this, it is essential to understand the biosynthetic pathway of PGE2, as well as 
the intracellular signalling pathways that regulate its enzymes.  
 
Prostaglandin E2 biosynthesis 
The biosynthesis of PGE2 involves three different groups of enzymes acting sequentially 
(see Figure 4, page 8). The first group of enzymes, phospholipase A2 (PLA2), converts 
membrane lipids to AA.115,116 The second group of isoenzymes is the cyclooxygenases 
(COX), which convert AA to prostaglandin H2 (PGH2).117 The intermediate prostaglandin 
PGH2 is in turn metabolised to diverse prostaglandins, including PGE2, PGF2, PGD2, and 
PGI2, by multiple enzymes.117,118 The third group of isoenzymes, prostaglandin E synthase 
(PGE synthase), which is the terminal enzyme in the synthesis of PGE2, catalyses the 
conversion of COX-derived PGH2 to PGE2.119,120  
 
Phospholipase A2 
The first step of PGE2 synthesis is the conversion of membrane lipids into AA, a reaction 
which is catalysed by the PLA2 enzymes. Of the more than 20 currently identified 
mammalian intracellular PLA2 isoforms, cPLA2α (systematically termed Group IV A PLA2 
or GIVA PLA2 for short) is the main player in AA release.121 The first GIVA PLA2 was 
identified in 1986 in human platelets122 and was cloned and sequenced in 1991.123 The 
cPLA2α enzyme is recruited to intracellular membranes by a Ca2+-dependent process.124 It 
can be activated by many different signals, including phosphorylation and the second 
messenger phosphatidylinositol.124 The expression of cPLA2(alpha?) can be stimulated by 
TNFα or IL-1β, as demonstrated in several cell types, including gingival fibroblasts and 
rheumatoid synovial fibroblasts.125,126 Insights into the role of cPLA2α can be obtained 
from studies of knockout mice, demonstrating that the effects of many inflammatory 
conditions are reduced, including damage from acute lung injury, collagen-induced 
arthritis and inflammatory bone resorption.127-129 High levels of PLA2 activity in the GCF 
of patients with periodontitis have been shown to decrease after periodontal treatment.130 
Moreover, secretory PLA2, sPLA2, is present in increased amounts in the synovial fluids 
and sera of patients with rheumatoid arthritis,131,132 further emphasising the role of PLA2 
enzymes in inflammatory conditions. Several cPLA2α inhibitors have been developed and 
beneficial effects have been observed in models of inflammatory conditions including 
rheumatoid arthritis and osteoarthritis.133 Pharmaceuticals such as darapladib and 
varespladib, which inhibit lipoprotein-associated PLA2 and sPLA2, respectively, are 
currently undergoing clinical studies for use in atherosclerosis.134,135 However, inhibition of 
PLA2 affects the synthesis of all prostanoids and leukotrienes, which may result in 
unwanted side-effects. Bearing this in mind, we now move further down the cascade of 
PGE2 synthesis. 
 
Cyclooxygenase 
The cyclooxygenases converting PLA2-derived AA to PGH2 have currently been described 
in two different isoforms, COX-1136 and COX-2.137,138 COX-1 is mainly involved in 
immediate prostaglandin production, initiated by agonists that cause a rapid burst of AA 
by affecting intracellular Ca2+.124 It is constitutively expressed in most tissues and is 
involved in maintaining tissue homeostasis. COX-1 expression has been shown to be 
unaffected by inflammatory stimuli in several cell types in vitro, including gingival 
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fibroblasts.58,139-141 The second isoform, COX-2, is essential for delayed prostaglandin 
production, where AA, induced by pro-inflammatory stimuli, is gradually released over 
longer time periods.142,143 However, COX-2 can also be involved in immediate 
prostaglandin synthesis if its expression has already been increased through inflammatory 
stimuli.143 The importance of the COX-2 isoform in inflammation is further indicated by 
its observed up-regulation in several chronic inflammatory conditions such as rheumatoid 
arthritis, Crohn’s disease and periodontitis.144-146  
The COX enzymes are located in the endoplasmic reticulum (ER) and nuclear 
envelope, with COX-2 more concentrated in the nuclear envelope.147 COX-1 and COX-2 
are 60% identical in amino acid sequence and their three-dimensional structures are almost 
superimposable. A splice variant of the COX-1 gene, retaining an intron which is not 
included in COX-1 mRNA, has been putatively termed COX-3 and suggested as a 
possible target for acetaminophen in canine systems.148 However, the relevance of these 
data to the human context has been questioned and, since the inclusion of the intron 
causes a shift in the reading frame resulting in a severely truncated enzyme with no COX 
activity, the importance of the so-called COX-3 enzyme appears to be very limited.149  
The COX-1 and COX-2 enzymes convert AA to PGH2 in two steps, each catalysed by 
a separate active site of the enzyme.150 First, the cyclooxygenase active site catalyses the 
formation of the intermediate PGG2 from AA. Then, at the peroxidase active site of the 
COX enzyme, PGG2 is reduced to PGH2. As first suggested by Nobel laureate John R. 
Vane in 1971,151 the cyclooxygenases are the primary targets for NSAIDs such as aspirin. 
NSAIDs inhibit the first step of the reaction, the formation of PGG2. Specific COX-2 
inhibitors have been developed to achieve inhibition of inflammation-induced PGE2 
production without the detrimental inhibition of baseline, COX-1-derived prostaglandin 
production thought to account for the gastrointestinal side-effects of traditional 
NSAIDs.150 However, it has been shown that these drugs also have several side-effects, 
including cardiovascular problems,152 and one of the COX-2-specific pharmaceutical 
inhibitors, Vioxx, was withdrawn from the market due to these side-effects. The problems 
experienced when inhibiting the COX enzymes draw our attention even further down the 
cascade of PGE2 synthesis.  
 
The terminal step in PGE2 biosynthesis is catalysed by the PGE synthases. Currently, three 
different PGE synthases have been identified and cloned; the inducible, microsomal and 
glutathione-dependent PGE synthase, mPGES-1,119,153 the constitutively and widely 
expressed cytosolic PGE synthase, cPGES,154 and the later characterised membrane-
associated and glutathione-independent PGE synthase, mPGES-2.155 
 
Microsomal prostaglandin E synthase-1 (mPGES-1) 
The identification of mPGES-1 was reported in 1999 by Per-Johan Jakobsson et al. at 
Karolinska Institutet.119 The expression of mPGES-1 under normal conditions is low in 
most tissues,119 but it increases considerably after inflammatory stimuli such as TNFα, IL-
1β or LPS, leading to increased PGE2 synthesis.76,156-161 The involvement of mPGES-1 in 
inflammatory conditions such as rheumatoid arthritis162,163 and gastritis,158 as well as in 
carcinogenesis164,165 has been demonstrated, but limited information is available regarding 
the role of mPGES-1 in periodontitis. In vitro, the induction of mPGES-1 in response to 
IL-1β and TNFα has been reported in various cell types, including cultured gastric 
fibroblasts, synovial fibroblasts, cardiac fibroblasts, gastric cancer cell lines, monocytes and 
   13 
gingival fibroblasts.76,157-161,166,167 Furthermore, studies have suggested that mPGES-1 
displays functional coupling with COX-2 to promote delayed PGE2 synthesis.168,169 This 
suggestion is supported by the findings that mPGES-1 and COX-2 are co-induced by 
inflammatory stimuli in mouse macrophages and osteoblasts, fibroblasts, chondrocytes and 
cancer cells.170-172 However, the absoluteness of this coupling has been questioned and a 
lack of exclusive co-ordination between these two enzymes has been reported.173-175 
The mPGES-1 enzyme is a 16 kDa membrane-spanning protein, which requires the co-
factor glutathione to function.119 It is located in the ER and the perinuclear area and 
appears to be co-localised with COX-2,143,168 possibly facilitating the concerted action of 
these enzymes in inflammation-induced PGE2 synthesis. The role of mPGES-1 in 
inflammation-induced PGE2 has been studied using antisense oligonucleotides blocking 
mPGES-1, as well as mPGES-1 knockout mice.176-178 In most respects, the knockout mice 
are indistinguishable from their wild-type littermates, apart from a marked difference in 
inflammatory reactions in disease models, such as collagen-induced arthritis and 
inflammatory pain.179 For instance, the effects of collagen-induced arthritis were greatly 
reduced in the knockout mice.179 Furthermore, in mPGES-1-null mice, no augmentation 
of PGE2 production was observed in response to LPS, indicating that mPGES-1 is essential 
for LPS-induced PGE2 production.176,178 In addition, blocking mPGES-1 expression using 
an antisense oligonucleotide inhibited osteoclastogenesis and bone resorption in mouse 
osteoblasts stimulated by the cytokines IL-1β and TNFα.170 Taken together, these findings 
indicate that mPGES-1 plays a crucial role in inflammation-induced PGE2 production and 
thereby also possibly in the pathogenesis of periodontitis. The endogenous and non-
endogenous regulation of mPGES-1 expression and activity will be discussed in detail in 
the next chapter. 
 
Membrane-associated prostaglandin E synthase-2 (mPGES-2) 
A glutathione-independent, membrane-bound PGE synthase isoform was observed in rat 
organs in 1997120 and this PGE synthase isoform, mPGES-2, was finally cloned and 
characterised in 2002.155 It is a homodimeric protein, where the molecular weight of each 
monomer is 33 kDa.155 It is synthesised as a Golgi membrane-associated protein, but the 
proteolytic removal of a hydrophobic N-terminal domain results in a mature cytosolic 
enzyme.143 In contrast to mPGES-1, the enzyme mPGES-2 appears to exhibit no selective 
coupling with COX-1 or COX-2.143 The mPGES-2 enzyme has not been as extensively 
studied as mPGES-1 and the expression and inducibility vary between different cell types, 
in response to different inflammatory stimuli.120,158,180,181 Knockout mice lacking the 
mPGES-2 gene display no decrease in PGE2 levels, indicating that this enzyme is not 
essential for in vivo PGE2 synthesis.182 However, a study by Kubota et al.183 of mPGES-1 
knockout mice indicated that mPGES-2 may play a compensatory role in inflammation-
induced PGE2 production in myometrium, substituting for mPGES-1. On the other hand, 
mPGES-2 expression was not increased by LPS treatment in microglia derived from 
mPGES-1 knockout mice in a study by Ikeda-Matsuo et al.,177 further highlighting the 
different roles of mPGES-2 in different tissues.  
 
Cytosolic prostaglandin E synthase (cPGES) 
The cytosolic PGE synthase was discovered in 1994184 as a conserved protein of broad 
tissue distribution with a molecular weight of 23 kDa, but its PGE synthase activity was 
first characterised in 2000.154 The enzyme cPGES is considered constitutively expressed, as 
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shown in various tissues, as well as in cultured cells such as gastric fibroblasts and 
rheumatoid synovicytes.154,158,185 Based on co-transfection studies, as well as the co-
localisation of cPGES and COX-1, these enzymes are considered to be functionally 
coupled.154,186 However, there have been reports of increased cPGES expression after LPS 
or IL-1β stimulation of rodent brain.154,187 Knockout mice lacking the cPGES gene do not 
survive the perinatal period.188 Although cPGES appears to be uninvolved in 
inflammatory-increased PGE2 synthesis in most tissues, a recent study suggests that cPGES 
might be involved in regulating the degradation of PGE2 in mouse embryonic fibroblasts 
and rat fibroblasts.189  
 
Regulation of mPGES-1 
Although the regulation of COX-2 and PGE2 production has been intensively investigated 
in various cell types, the signal transduction pathways regulating the expression of mPGES-
1 in relation to PGE2 have not been adequately explored. Various intracellular signalling 
pathways have been reported to be involved in inflammation-induced PGE2 production 
and in the expression of PGE2-sythesising enzymes, although these pathways appear to be 
both cell and stimulus specific. Protein kinase C (PKC) and mitogen-activated protein 
(MAP) kinases, including extracellular signal-regulated kinase (ERK) and p38 MAP kinase, 
have been reported to be involved in inducing mPGES-1 expression in IL-1β-stimulated 
colonocytes and orbital fibroblasts, as well as in rat aortic adventitial fibroblasts.190-192 The 
ERK and p38 MAPK pathways were also shown to be involved in IL-1β-stimulated 
mPGES-1 expression in human chondrocytes from patients with osteoarthritis.193 
However, mPGES-1 expression has been shown to be unaffected by PKC stimulation in 
gastric carcinoma cell lines161 and by the inhibition of p38 MAPK in cardiac fibroblasts,160 
which exemplifies the cell-specific nature of mPGES-1 regulation. In rat microglia, LPS-
induced mPGES-1 expression was shown to be mediated by the phosphatidylinositol 3-
kinase/Akt, PKC, c-Jun N-terminal kinase (JNK), and nuclear factor-κB (NF-κB) 
signalling pathways.194 The JNK pathway has also been shown to be involved in increased 
mPGES-1 expression in IL-1β-stimulated cells, such as cardiac fibroblasts and A549 
human lung epithelial cells.160,195  
The mPGES-1 promoter contains regulatory elements including activator protein-1, 
glucocorticoid receptor (GR) and early growth response-1 (Egr-1) binding sites.196,197 The 
transcription factors Egr-1 and NF-κB have been shown to be involved in the regulation of 
mPGES-1 expression in different cell types including HeLa cells, pulmonary A549 cells, 
murine osteoblastic cells and murine macrophages.172,198-200 In gingival fibroblasts, we have 
previously reported that the inflammatory mediators IL-1β and TNFα induce the 
expression of mPGES-1 in parallel with PGE2 production and that the glucocorticoid 
dexamethasone inhibits the expression of mPGES-1.157  
 
In addition to elucidating the endogenous regulation of the PGE synthases, great efforts 
have been made to develop a strategy for non-endogenous regulation of mPGES-1. 
Recently, several different groups of compounds inhibiting mPGES-1 activity have been 
described.201,202 One of the most promising groups of inhibitors are the disubstituted 
phenantrene imidazoles, which were also orally active in a guinea pig model.203 The indole 
5-lipoxygenase-activating protein inhibitor MK-886 and its derivatives have also been 
shown to inhibit mPGES-1 in enzyme assays and, less potently, inhibit PGE2 formation in 
cell-based assays.171,204,205 Furthermore, natural products such as curcumin206 (from the 
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spice turmeric) and epigallocatechin-3-gallate207 (from green tea) have been shown to affect 
mPGES-1 in vitro. Several mPGES-1 inhibitors are being tried out in animal models, but 
none are as yet available for use in humans.208-211 
To summarise the central points of this introduction, the product of PGE synthase, PGE2, 
is widely recognised as one of the key inflammatory mediators in the pathogenesis of 
periodontitis. The expression of PGE synthases has been studied in several diseases, 
including rheumatoid arthritis, colon cancer and gastritis. However, there are no previously 
published data on the expression of the three PGE synthases in periodontitis. Furthermore, 
there are no reports addressing the contribution of the different cells in the connective 
tissue to inflammation-induced PGE2 production. The signal pathways leading to 
increased mPGES-1 expression in response to inflammatory stimuli may represent targets 
for the possible interruption of the increase in PGE2 production in inflammation, which 
makes it important to study the intracellular pathways in a cell type relevant to the context 
of periodontitis.  
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Aims of the thesis 
 
 
General aim 
The general aim of this thesis was to investigate the expression and regulation of the PGE 
synthases in vivo in periodontitis-affected gingival tissue and in vitro in cell cultures.  
 
Specific aims  
Study I    
The aim of Study I was to investigate the localisation and expression of PGE2-producing 
enzymes, focusing on the PGE synthases (mPGES-1, mPGES-2 and cPGES), in inflamed 
human gingival connective tissue collected from patients with periodontitis. An additional 
aim was to investigate the regulation of these enzymes using in vitro models, mimicking an 
inflammatory situation. 
  
Study II 
The aim of Study II was to elucidate the impact of down-regulated mPGES-1 expression 
on the expression of the mPGES-2 and cPGES isoenzymes, as well as on PGE2 production, 
using small interfering RNA (siRNA) technology and chemical inhibition. 
 
Study III 
The aim of Study III was to investigate the intracellular regulation of mPGES-1 expression 
with special regard to PLA2, PKC, tyrosine kinases, p38 MAP kinase, prostaglandin 
metabolites and the transcription factors Egr-1, GR and NF-κB in gingival fibroblasts 
stimulated with the inflammatory cytokines TNFα and IL-1β. 
 
Study IV 
The aim of Study IV was to further explore the signal transduction pathways involved in 
the regulation of mPGES-1 and COX-2 in TNFα-stimulated primary gingival fibroblasts 
through a global gene expression approach, using microarray technology.  
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Materials and methods 
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his section gives a brief overview of the methods used to obtain the results 
presented in this thesis. The methods mainly focus on gene expression and the 
regulation of gene expression, focusing on the PGE synthases (Figure 7). For more 
detailed protocols, including in-depth details such as concentrations of substances and 
buffers, primer sequences or sources of chemicals, the reader is referred to the materials and 
methods sections of the published studies (I-IV). To facilitate the understanding of Studies 
I-IV by researchers unfamiliar with molecular methods, the principles underlying the 
methods are also briefly covered. 
 
T 
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Gingival tissues 
One way to investigate the inflamed gingival tissue is to remove biopsies for study. The 
gingival biopsies (approximately 2×2×2 mm) are sectioned into thin slices, which are 
mounted on microscope slides. Once mounted on slides, the biopsy sections can be stained 
with fluorescently labelled or enzyme linked antibodies, which bind specifically to the 
protein of interest. Together with stainings that reveal the tissue structure, these analyses of 
tissue sections provide us with information relating to whether and where our proteins of 
interest can be found in vivo.  
 
Gingival tissue collection (Study I) 
A total of 11 gingival tissue biopsies were obtained from adult patients (age 35-68) 
diagnosed with periodontitis but otherwise healthy. The inclusion criteria were clinical 
signs of periodontitis at the site of biopsy collection, including radiographic bone 
resorption, pocket probing depth of ≥ 6 mm and bleeding on probing. Biopsies were taken 
during surgery as part of the normal course of periodontal therapy. The study was 
approved by the ethical committee at Karolinska Institutet. Each patient gave his/her 
informed consent for the use of gingival tissue. 
 
Histological and immunohistochemical analysis (Study I) 
Paraffin-embedded gingival tissues were sectioned (4 µm) and sections of each biopsy were 
stained with haematoxylin and eosin, as well as Giemsa, in order to assess the orientation of 
the epithelium and the degree of cell infiltration. To investigate leukocyte infiltration in 
the biopsies, tissues were stained using antibodies against the CD45 surface antigen. To 
further assess the degree of inflammation, tissues were also stained with antibodies against 
the inflammatory cytokine IL-1β. The details of these staining procedures can be found in 
the methods section in Study I. 
 
For the immunostaining of PGE synthases and COX-2 in the biopsies, the sections were 
deparaffinised using xylene and were then rehydrated. Immunohistochemical staining was 
performed using primary antibodies for mPGES-1, mPGES-2, cPGES or COX-2. For 
negative controls, the primary antibody was substituted with an isotype-matched control 
antibody. After incubation with primary antibody, a biotinylated secondary antibody was 
added to the slides. The primary antibodies were mouse or rabbit IgG, while the secondary 
antibodies were anti-mouse or anti-rabbit, respectively. The biotinylation of the secondary 
antibody enabled streptavidin-conjugated horseradish peroxidase (HRP) to bind to the 
antibody complex. Addition of the HRP substrate 3,3' diaminobenzidine then resulted in 
the formation of a brown-coloured product in areas where the protein of interest was 
expressed. The slides were then mounted and observed under a light microscope. 
 
To identify mast cells in the tissue, sections were deparaffinised and stained either with 
0.5% toluidine blue in McIlvaine’s buffer (pH 4) or with anti-human mast cell tryptase, 
using an automated instrument. 
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Immunofluorescent double staining (Study I) 
Gingival tissues were immediately snap-frozen in liquid nitrogen, and then cryostat 
sectioned (7 µm). The sections were then fixed, permeabilised and blocked. After blocking, 
the slides were incubated with a mixture of two primary antibodies consisting of anti-
mPGES-1 (polyclonal rabbit) and antibodies targeting the fibroblast marker anti-prolyl-4-
hydroxylase, the endothelial cell marker von Willebrand factor, or smooth muscle actin (all 
monoclonal mouse). After washing, the sections were incubated with a mixture of 
secondary antibodies conjugated with fluorophores. The anti-rabbit secondary antibody 
was conjugated with Alexa Fluor 594 (red) and the anti-mouse secondary antibody was 
conjugated with Alexa Fluor 488 (green). The slides were washed, mounted and observed 
using a fluorescence microscope and image analysis was performed with the NIS-Elements 
software package. For all experiments, isotype-matched irrelevant antibodies were used as 
negative controls in the staining procedures. 
 
Cell cultures 
Cell cultures are useful model systems that serve as our substitute for the real live tissue of a 
real live patient. Cell cultures naturally lack characteristics that define the tissue, such as 
several interacting cell types, a tissue structure and an extracellular matrix. On the other 
hand, the cell culture model system readily lends itself to experimentation which may be 
neither ethical nor practical to perform on patients. Using cell cultures, the reactions of a 
specific cell type to a specific set of stimuli can be studied in isolation, thereby facilitating 
the elucidation of the complex network of interactions that contribute to the process of 
chronic inflammation. This section describes the cell culture of primary human gingival 
fibroblasts, as well as our treatment of the cells with a wide range of biological and 
chemical substances affecting the cells in various ways.  
 
Gingival fibroblasts (Studies I-IV) 
Human gingival fibroblasts were established from gingival biopsies obtained from healthy 
patients with no clinical signs of periodontal disease. Minced pieces of gingival tissue were 
explanted to tissue culture flasks containing culture medium including serum and 
antibiotics. Gingival fibroblasts were obtained by trypsinisation of the primary outgrowth 
of cells from the minced pieces of gingival tissue. The cells were then grown at 37°C with 5 
% CO2 and routinely passaged by trypsinisation.  
 
Gingival fibroblasts were seeded in Petri dishes or cell culture plates, using culture medium 
supplemented with serum, and cultured for 24 h at 37°C. The cell layers were then rinsed 
with serum-free culture medium followed by the treatment of the cells with one of the 
inflammatory cytokines IL-1β or TNFα, in the presence or absence of substances 
summarised in Table 1. The cells were incubated for different time periods, ranging from 
10 minutes to 24 h. In Study I, only IL-1β or TNFα were used, on different cell types. In 
Study II, the cells were treated with the inflammatory cytokines in combination with MK-
886 or as described under “Knock-down of mPGES-1 by small interfering RNA (siRNA)” 
below. In Study III, various chemicals affecting intracellular signalling pathways were used, 
as well as components of the prostaglandin pathway. In Study IV, TNFα was used in a 
time series of experiments for microarray analysis, followed by further time-series 
experiments, including inhibitors of the JNK and NF-κB signalling pathways. After  
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 Used in study
Name Effect I II III IV
IL-1β inflammatory cytokine X X X X 
TNFα inflammatory cytokine X X X X 
MK-886 mPGES-1 inhibitor  X   
dexamethasone (Dex) anti-inflammatory glucocorticoid  X X  
15-deoxy-∆ (12,14)-prostaglandin J2  
(15d-PGJ2) 
anti-inflammatory prostaglandin 
  
X 
 
4-bromophenacyl bromide (BPB) PLA2 inhibitor   X  
arachidonic acid (AA) prostaglandin precursor   X  
bisindolylmaleimide (BIS) PKC inhibitor   X  
PD 153035 hydrochloride (PD) tyrosine kinase inhibitor   X  
phorbol-12-myristate-13-acetate (PMA) PKC activator   X  
prostaglandin E2 (PGE2) inflammatory mediator   X  
prostaglandin F2α (PGF2α) prostaglandin downstream of PGE2   X  
pyrrolidine dithiocarbamate (PDTC) NF-κB inhibitor   X  
SB 203580 (PD) p38 MAPK inhibitor   X  
Bay 11-7082 (Bay) NF-κB inhibitor    X 
Ro 106-9920 (Ro) NF-κB inhibitor    X 
SP600125 (SP) JNK inhibitor    X 
 
Table 1. Substances used to treat gingival fibroblasts. The substances in this table were 
used to treat the cells in Studies I-IV. 
 
treating the cells for the different incubation periods, culture medium was removed and 
stored at -20°C for subsequent analysis. The cell monolayer was washed and cells were 
collected for flow cytometric analysis, lysed for protein isolation, or lysed for isolation of 
total RNA. 
 
Smooth muscle cells, endothelial cells, mast cells and mouse gingival fibroblasts 
(Study I) 
The main cell type used for the in vitro experiments throughout this thesis is human 
gingival fibroblasts (Studies I-IV). For the isolation and culture procedures of human 
umbilical vein endothelial cells, human airway smooth muscle cells, mast cells and 
mPGES-1 knockout mouse gingival fibroblasts, the reader is referred to the methods 
section in Study I. 
 
Co-cultures (Study I) 
In Study I, cells were also co-cultured with lymphocytes isolated from whole blood, as an 
in vitro model of inflammation. Fibroblasts, endothelial cells or smooth muscle cells were 
seeded in Petri dishes. The cells were rinsed and cultured either alone or in co-culture with 
lymphocytes suspended in culture medium. The lymphocytes grow in suspension, whereas 
the other cells adhere to the surface of the Petri dish. Both direct cell-to-cell contact and 
interaction by soluble mediators is possible between the cell types in this co-culture system. 
After 18 hours of incubation, the co-culture medium containing lymphocytes was removed 
and centrifuged, after which the medium was collected and stored at -20°C for PGE2 
measurements. Fibroblasts, endothelial cells or smooth muscle cells were trypsinised and all 
cell types were collected and analysed by flow cytometry. 
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Knock-down of mPGES-1 by small interfering RNA (siRNA) 
(Study II) 
The method of siRNA gene knock-down is based on a mechanism which is present in 
many eukaryotic species to regulate endogenous genes and to defend the genome from 
invasive nucleic acids.212 The mechanism of gene knock-down, as illustrated in Figure 8, is 
dependent on the assembly of the RNA-induced silencer complex (RISC). One strand of 
the double-stranded RNA is integrated into RISC and the other strand is degraded. The 
RISC with a bound siRNA recognises the complementary mRNA and cleaves it, thereby 
preventing translation and effectively knocking down the protein expression of the target 
gene. In Study II in this thesis, siRNA was introduced into the cells using a transfection 
reagent. The transfection reagent incorporates the siRNA into vesicles which can then fuse 
with the cell membrane to enable the siRNA to enter the cytoplasm. The laboratory 
procedure for siRNA experiments is outlined in Figure 9. Briefly, gingival fibroblasts were 
transfected with siRNA targeting mPGES-1 or mock transfected without siRNA. To allow 
the cells to recuperate after the transfection, a recovery period of 6 h was then allowed 
before the cells were stimulated with either of the cytokines TNFα or IL-1β. After 
stimulation, culture medium was removed and stored at -20°C for subsequent PGE2 
determination and the cells were harvested for flow cytometric, western blot or activity 
analysis.  
 
RNA expression analyses 
In each human being, the DNA, our genome, is the same in a fibroblast of the gingiva and, 
for instance, a neuron of the brain. The difference between the cells is accounted for to a 
large extent by differences in gene expression; i.e. the actual “building” of the proteins from 
the “blueprints” of the genome. Genes that are not transcribed into mRNA and 
subsequently translated into protein are unable to perform a function in the cell. There are 
several different methods for measuring gene expression. For the analysis of mRNA levels, 
the crucial improvement of the polymerase chain reaction (PCR) by Nobel laureate Kary 
B. Mullis and co-workers in the mid-1980s213,214 allowed for its use in molecular biology 
and opened up a whole new world of opportunities. With the ability to amplify the 
amount of a specific DNA sequence to a level at which it is readily detectable, mRNA, 
converted to complementary DNA (cDNA), could be visualised using agarose gels and 
ethidium bromide. Another breakthrough in the analysis of mRNA gene expression was 
the first microarray, which was described in 1995.215 This first microarray consisted of 45 
gene transcripts spotted on a glass slide, but today the number of spots on a microarray 
chip can be three orders of magnitude larger. Microarray platforms enable the 
simultaneous analysis of mRNA gene expression using a comparatively small amount of 
sample. The two methods, reverse transcription PCR and oligonucleotide microarray 
analysis, are used for the analysis of mRNA expression in this thesis. However, the 
development of new techniques is ongoing and our group and others now rely 
progressively on sequencing methods for gene expression profiling.  
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RNA isolation and reverse transcription PCR (Studies II and III) 
Gingival fibroblasts were seeded in Petri dishes and grown as described under the “cell 
culture” section. After 6 h of incubation with or without treatment, total RNA was isolated 
from gingival fibroblasts using the commercially available RNeasy kit and quantified 
spectrophotometrically at 260/280 nm. To obtain first-strand cDNA, RNA was reverse 
transcribed using the enzyme reverse transcriptase. The cDNA was then used as a template 
for PCR amplification. As a control, the housekeeping gene GAPDH was also amplified. 
From each PCR reaction product, 10 µl was separated on an agarose gel with ethidium 
bromide, together with a DNA-ladder standard. Ethidium bromide binds to DNA and 
fluoresces when irradiated with UV light, thereby enabling the visualisation of the PCR 
products. For each experiment, PCR amplifications without cDNA were performed as 
negative controls. 
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Microarray analysis (Study IV) 
In a microarray analysis, the mRNA expression of a large number of genes is analysed 
simultaneously. The microarray itself looks like a regular glass slide but contains tens of 
thousands of tiny spots of DNA. In the microarray chip used in this analysis, each spot, or 
feature, contains a large number of copies of a single 70 bp long sequence of DNA, which 
maps to a specific gene of the human genome. There are 35,344 features representing 
28,948 Entrez Gene IDs216 of which 17,972 are unique. The microarrays were printed at 
the KTH microarray core facility. 
  
To obtain samples for microarray analysis, three separate cell lines of gingival fibroblasts 
were seeded in Petri dishes. After incubation for 1, 3 or 6 h with or without TNFα, the 
cells were immediately frozen in liquid nitrogen and then stored at -70°C for the 
subsequent isolation of total RNA. Total RNA was isolated from fibroblasts using the 
commercially available RNeasy kit and quantified spectrophotometrically at 260/280 nm. 
Synthesis of cDNA was then performed using the RNA from each sample as template. In 
the cDNA synthesis reaction, aminoallyl nucleotides were used and, after the cDNA 
synthesis, these were coupled to fluorophores, thus fluorescently labelling the samples. Two 
fluorophores were used, Cy3 (red) and Cy5 (green). To analyse the cDNA using the 
microarray, the samples are hybridised in pairs (one green and one red) to each microarray 
slide, as illustrated in Figure 10. The cDNA of the samples then bind to each spot on the 
array and the sample with the highest expression of a particular gene subsequently has the 
largest amount of fluorescently labelled cDNA bound to that spot.  
 
After the hybridisation step, the microarray slides are scanned, resulting in two images – 
one red image, where the different intensities of Cy3 are shown for each spot, and one 
green image for Cy5. The images are combined and analysed using image analysis software 
which produces a ratio between red and green intensities for each spot. Statistical methods 
are then used to combine the data from all hybridisations and identify differentially 
expressed genes in different comparisons. A microarray experiment can be set up in many 
different ways, using different hybridisation combinations of the samples. For Study IV we 
chose a time-course factorial study design (Figure 11), optimised to estimate the 
interaction effect between TNFα treatment and time.217  
 
The statistical analysis of microarray data was performed using the open source software 
R,218 using different software packages, including the KTH package and packages from the 
Bioconductor open source software project for analysis of genomic data.219 Four filters were 
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first used to remove spots with abnormal physical properties. On average, 75% of all spots 
passed the filters for each slide. After filtering, the slides were normalised using print tip 
Lowess normalisation and a moderated t-test was used to identify differentially expressed 
(DE) genes.220,221 A false discovery rate algorithm was then applied to correct for multiple 
testing.222 Thereafter, differentially expressed genes were defined as genes with a q-value 
(the false discovery rate analogue of a p-value) of < 0.05, meaning that the proportion of 
false positives among the differentially expressed genes was 0.05.  
 
To discern the patterns present within the DE genes in our dataset, we performed an 
enrichment analysis, using the Gene Ontology (GO) database.223 The GO database is a 
structured controlled vocabulary (ontology) describing gene products in terms of their 
associated biological processes, cellular components and molecular functions. We used GO 
to assign functions to the DE genes in our dataset.223 We then utilised the GO annotation 
in performing an enrichment analysis to discover biological themes among the DE genes in 
the different comparisons.224 In the enrichment analysis, groups of genes linked to a 
particular GO term, such as “immune response”, are analysed to see whether more of the 
genes in that group are DE in our dataset than would be expected by chance. This analysis 
enables us to obtain an overview of the vast amounts of data obtained from the series of 
microarray analyses.  
 
Protein expression analyses  
The analysis of mRNA levels is a very useful method for detecting gene expression. To 
analyse a specific gene, good primers for the PCR reaction is the main requirement. 
Furthermore, the analysis of mRNA levels is readily multiplexable. However, what 
generally matters most in the cell is the amount of protein translated from the mRNA in 
question. For enzymes like the PGE synthases, the protein is what performs the actual 
catalysis of the reaction. However, protein levels are commonly more difficult to determine 
than mRNA levels. All the approaches used to measure protein levels in this thesis are 
based on antibodies. Antibodies are large Y-shaped proteins used by our immune systems 
to identify and neutralise pathogens such as bacteria or viruses. Antibodies that bind 
specifically to a particular protein can be produced and used in research applications. 
Polyclonal and monoclonal antibodies are used in the studies included in this thesis for 
western blotting and flow cytometric analyses, as well as for tissue staining (as described in 
the “Histological and immunohistochemical analysis” section). Primary antibodies are used 
to bind specifically to the protein of interest. Then, to detect the primary antibodies, 
secondary antibodies are allowed to bind to the primary antibodies. These secondary 
antibodies are conjugated to a reporter, often a fluorophore or an enzyme, such as HRP, 
which is able to catalyse a reaction forming a coloured product. HRP can also be used to 
catalyse a reaction forming a light-emitting product (chemiluminescence), the presence of 
which can be recorded on a photographic film.  
 
Western blotting (Studies I-IV) 
Cells were seeded and grown as described under the “cell culture” section. To isolate the 
total protein, the cells were washed with PBS and resuspended in lysis buffer containing 
protease inhibitors. The protein concentration of the cell lysates was determined and equal 
amounts of the obtained protein were separated by electrophoresis on a 4-15% linear 
gradient polyacrylamide tris-HCl gel or a 10% sodium dodecyl sulphate-polyacrylamide 
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gel. The protein was then transferred to a nitrocellulose membrane which was blocked and 
then incubated over night with primary antibody (mPGES-1, mPGES-2, cPGES or COX-
2). Following primary antibody incubation, the membranes were washed and then 
incubated with HRP-conjugated secondary antibody. The membranes were washed, 
developed using chemiluminescence and exposed to hyperfilm-ECL. 
 
Flow cytometry (Studies I, II and IV) 
Cells were seeded and grown as described in the “cell culture” section. After treatment, the 
cells were collected by trypsinisation and/or centrifugation of culture medium depending 
on cell type and washed with PBS. Thereafter, the cells were fixed in paraformaldehyde 
and permeabilised using saponin. Saponin allows the antibodies to pass through the cell 
membrane, enabling the staining of intracellular proteins like the PGE synthases. The cells 
were then incubated with primary antibodies for mPGES-1, mPGES-2, cPGES or COX-
2. After incubation and washing, the cells were further incubated with a secondary, 
fluorescently labelled antibody. Cells could then be analysed in a flow cytometer for the 
expression of mPGES-1, mPGES-2, cPGES or COX-2. The flow cytometer analyses each 
cell separately, recording the forward scatter (giving information on cell size) and the side 
scatter (pertaining to cell granularity), as well as the fluorescence at different wavelengths. 
The forward and side scatter parameters in this setting serve to confirm that we have only 
one cell type in our sample. The fluorescence intensity is related to the expression of the 
analysed protein. The results obtained are shown as histograms of cell counts, drawn using 
the program R, together with the software package rflowcyt,218,219 or presented as mean 
fluorescence intensity.  
 
Activity analyses 
Although the amount of a specific enzyme may have a great impact on its effect on the cell, 
the activity of an enzyme can be even more important. Taking protein kinases as an 
example, these enzymes lie dormant in the cell until they are activated, for instance by 
phosphorylation. The activated kinase is then able to phosphorylate other downstream 
enzymes, in turn activating them. This process results in intracellular signalling cascades 
which are much faster than would be possible if the signal depended on the de novo 
synthesis of the enzymes involved. However, the amounts of enzyme present before 
activation can still affect the strength of the signal.  
 
Phosphorylation-specific analysis (Study IV) 
To confirm that certain intracellular signalling pathways were activated by TNFα 
treatment of the cells, and also to confirm the inhibition of these signalling pathways by 
specific inhibitors, we used antibodies that specifically bind only to the phosphorylated, i.e. 
activated, form of the enzyme. Since kinase phosphorylation is such a rapid process, both 
short and long incubation times were used. Cells were seeded and grown in Petri dishes as 
described above. After an incubation period of 10 minutes, 1 h, 3 h, 6 h or 24 h, the cells 
were scraped in PBS and centrifuged. The pellet was then resuspended in lysis solution, 
containing protease and phosphatase inhibitors, and frozen at 20°C. The samples were 
then thawed and centrifuged and the supernatant was collected. The lysate protein 
concentration was determined, followed by the addition of an equal volume of assay buffer 
from the Bio-Plex phosphoprotein detection kit. The samples were then frozen at -20°C 
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until determination of the amount of phosphorylated JNK or NF-κB using Luminex 
technology on a Bio-Plex Suspension Array System.  
 
PGE synthase activity assay (Study II) 
The function of the PGE synthase enzymes is to convert PGH2 to PGE2. This reaction can 
be performed outside the cell as an in vitro enzyme assay, to evaluate the PGE synthase 
activity in the cell lysate from a specific cell culture experiment. To achieve this, gingival 
fibroblasts were seeded in Petri dishes and treated with TNFα or IL-1β, or as described 
under “knock-down of mPGES-1 by small interfering RNA (siRNA)”. After treatment, 
the cells were collected by trypsinisation and were then lysed by freeze-thawing and 
sonication. In the activity assay, equal amounts of protein from each sample were 
incubated with PGH2 in Tris buffer supplemented with glutathione. The reaction was 
allowed to proceed for 60 s at room temperature and was thereafter terminated by the 
addition of FeCl2 which decomposes the remaining PHG2 to non-relevant metabolites.225 
Following centrifugation, the supernatants were collected and frozen (-20°C) for 
subsequent PGE2 analysis. For negative controls, the reaction was run without cell lysate.  
 
Analyses of culture media 
The cells in our in vitro studies grow in culture medium. When we perform experiments, 
substances are added to the culture medium and these substances affect the cells. However, 
the cells also affect the culture medium by releasing a range of compounds in response to 
treatment. The medium that we collect after treatment of the cells can therefore give us 
information on the processes inside the cells, such as the production of PGE2.  
 
Prostaglandin analysis (Studies I-IV) 
The radioimmunoassay (RIA) and enzyme immunoassay (EIA) are both antibody-based 
methods. The difference lies in the detection of the antibodies after they have bound to the 
molecule of interest, for example PGE2. RIA uses radioactive labelling, which can be 
measured using a gamma counter. EIA uses an enzymatic reaction, resulting in a coloured 
product which can be measured spectrophotometrically. The amount of PGE2 in the 
culture media was determined using an RIA kit, a conventional EIA kit or using Luminex 
technology on a Bio-Plex Suspension Array System with a commercially available EIA kit. 
The amount of PGF2α in the culture media was determined using an EIA kit (Study II). 
The amount of PGE2 produced in the activity assay (Study II) was measured using 
Luminex technology on a Bio-Plex Suspension Array System with a commercially available 
EIA kit.  
 
Analysis of 3H-arachidonic acid (3H-AA) release (Study II) 
Analysing AA release gives us information on the total amount of eicosanoids 
(prostaglandins and leukotriens) produced by the cell. It was used in conjunction with 
siRNA knock-down experiments in Study II. After the transfection and recovery of the 
cells, but before stimulation with cytokines, a 20-hour incubation period was introduced 
into the normal siRNA protocol (see Figure 9, page 24 for the siRNA protocol). During 
this incubation period, AA labelled with 3H was added to the culture medium and thus 
incorporated into the cells. The cells were then stimulated with TNFα for 24 h after which 
the culture medium was collected and analysed for levels of 3H using a scintillation 
counter. To obtain the total activity, cell layers were lysed and analysed using a scintillation 
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counter. The results were presented as 3H release divided by total 3H activity (medium and 
cells), relative to control cells. An increased value represents an increase in AA-derived 
products such as prostaglandins secreted by the cells. The activity of 3H represents free 3H-
AA, as well as 3H-labelled metabolites. 
 
Statistical analyses 
For statistical analyses other than those used for microarray data (Study IV), we used 
Student’s t test (two-tailed). The t test was first introduced in the early 19th century by 
William Sealy Gosset who used “Student” as his pen name in order to hide the fact that he 
had developed the statistics as an aid to monitoring the quality of stout at the Guinness 
brewery in Dublin, Ireland. In this work, all cell culture experiments were analysed in 
triplicate and reproducible data representing one of at least three independent experiments 
were demonstrated. The results are expressed as the mean value ± standard deviation. p-
values of less than 0.05 were considered statistically significant.  
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he four studies included in this thesis investigate the expression and regulation of 
PGE synthases in periodontitis-affected gingival tissue and in gingival fibroblasts. 
Study I deals with the in vivo expression of PGE synthases in gingival tissue 
collected from patients with periodontitis, as well as the in vitro expression and regulation 
of the enzymes in various cell types. In Study II, a possible inter-regulation of the three 
PGE synthase isoforms is investigated by means of siRNA knock-down of mPGES-1 in 
vitro using human gingival fibroblasts, the predominant cell type in gingival connective 
tissue. Studies III and IV further explore the regulation of the inducible PGE synthase 
isoform, mPGES-1, in gingival fibroblasts. All four studies have been published in peer-
reviewed journals and can be found in their entirety in the appendix. This section gives a 
brief overview of the results of these studies and a discussion of the findings in relation to 
the current literature. 
  
 
T 
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Expression of prostaglandin E synthases in periodontitis-
affected gingival tissue (Study I) 
PGE2 is a key mediator in several chronic inflammatory conditions including 
periodontitis.91-94 A group of isoenzymes in the prostaglandin E cascade, the PGE 
synthases, catalyse the terminal step of PGE2 biosynthesis. The in vivo expression of all 
three PGE synthase isoforms, mPGES-1, mPGES-2 and cPGES, has not been previously 
investigated in gingival tissue, although mPGES-1 has been shown to be expressed in 
gingivitis.226 The upstream enzyme COX-2, which has been more thoroughly studied, has 
also been shown to be expressed in gingivitis as well as in periodontitis.145,226 We studied 
the expression of PGE synthases in inflamed gingival tissue from patients with 
periodontitis, finding the protein expression of the isoforms mPGES-1, mPGES-2 and 
cPGES, as well as COX-2, in epithelium, fibroblasts, endothelial cells, vascular smooth 
muscle cells and inflammatory cells. No previous data on the expression of mPGES-2 or 
cPGES in inflamed gingiva have been published. However, our results relating to the in 
vivo localisation of mPGES-1 and COX-2 are consistent with previous studies showing the 
positive staining of these inducible enzymes in epithelial, endothelial, and fibroblast-like 
connective tissue cells of the gingiva.226,227 These results from Study I are also in accordance 
with findings in synovial tissue from patients with rheumatoid arthritis228 and gastric ulcer 
tissue158, emphasising the importance of the PGE synthases in diverse chronic 
inflammatory conditions. Our finding that all three PGE synthases are expressed in 
inflamed gingival tissue from patients with periodontitis suggests that all three enzymes 
may contribute to PGE2 synthesis in gingival tissue. We then proceeded to investigate the 
regulation of PGE synthases in vitro, further exploring their role in inflammation-induced 
PGE2 synthesis.  
 
Cellular regulation of PGE2 production (Study I) 
Levels of PGE2 have been shown to be enhanced in gingival tissue from patients with 
periodontitis, highlighting PGE2 as a key inflammatory mediator involved in this chronic 
inflammatory condition.92 We showed that all three PGE synthases are widely expressed in 
gingival tissue from patients with periodontitis. To further explore the cellular regulation 
of the PGE synthases and PGE2 production in gingival connective tissue, we used cell 
cultures stimulated with the inflammatory cytokines TNFα or IL-1β as an in vitro model 
of inflammation in terms of PGE2 synthesis. The cell cultures used as in vitro models were 
primary human gingival fibroblasts, endothelial cells (human umbilical vein endothelial 
cells, HUVEC, of the CRL-1730 cell line), smooth muscle cells (primary human airway 
smooth muscle, HASM, cells) and mast cells (the HMC-1.2 human mast cell line and 
primary human cord blood mast cells). The results showed the protein expression of 
mPGES-1, mPGES-2, cPGES and COX-2, as well as basal levels of PGE2 production, in 
cultured gingival fibroblasts, endothelial cells, smooth muscle cells and mast cells. 
Moreover, the expression of mPGES-1 and COX-2 was increased by TNFα and IL-1β in 
fibroblasts and smooth muscle cells, whereas, in endothelial cells, only COX-2 was 
induced, in response to TNFα. The up-regulated expression of the PGE2-synthesising 
enzymes mPGES-1 and COX-2 was accompanied by enhanced PGE2 production in 
fibroblasts and smooth muscle cells and, to a lesser extent, also in endothelial cells. 
Epithelial cells were not included in the in vitro studies, since our focus was on gingival 
connective tissue. Previous studies have shown increased PGE2 production in gingival 
epithelial cells after stimulation with bacterial components.229,230 
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In cytokine-stimulated gingival fibroblasts, the observed increase in PGE2 production via 
the enhanced expression of mPGES-1 and COX-2 is in agreement with data on synovial, 
orbital and gastric fibroblasts, as well as our previous data on gingival fibroblasts.58,157,191,231-
233 The information from our results, together with the above-mentioned studies of 
fibroblasts from other tissues, support the concept that fibroblasts play an important role in 
the inflammatory reaction instead of being solely involved in tissue homeostasis, as 
previously believed.36,234 The facts that fibroblasts are prominent producers of PGE2, as well 
as the most ubiquitous cell type in gingival connective tissue, further highlight these cells as 
possible attractive targets in the treatment strategy for periodontitis. The targeting of 
fibroblasts in the treatment of chronic inflammatory diseases has also been suggested by 
Flavell et al., who proposed that fibroblasts might be stimulated to produce pro-resolution 
mediators instead of inflammatory products.36  
 
Regarding smooth muscle cells, our in vitro results showed that PGE2 production and 
PGE2-synthesising enzymes are up-regulated in HASM cells in response to TNFα and IL-
1β. These results are in line with previous studies of primary human vascular smooth 
muscle cells, showing that mPGES-1 and COX-2 are induced by inflammatory 
cytokines.175,235 Cultured endothelial cells, however, had only a modest basal production of 
PGE2, which was slightly induced by TNFα but not by IL-1β. Up-regulation of COX-2 
but not mPGES-1 expression accompanied the increase in PGE2 production, which 
suggests that the mPGES-1 and COX-2 enzymes are regulated by different mechanisms in 
the endothelial cells. The issue of differential regulation of mPGES-1 and COX-2 
expression will be further discussed in the section “Signal transduction pathways of 
cytokine-induced mPGES-1 expression in gingival fibroblasts”. Our results regarding 
regulation of PGE2-synthesising enzymes in endothelial cells are similar to previously 
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published data demonstrating the up-regulation of COX-2 in response to TNFα.236 
However, it has been reported that endothelial cells from saphenous vein do not express 
mPGES-1 mRNA, even after cytokine stimulation,235 which may suggest a location-
specific expression of PGE synthases in endothelial cells. The in vitro results showing the 
production of PGE2 by the vascular cell types endothelial cells and smooth muscle cells 
suggest a possible role for these cells in inflammation-induced PGE2 production in vivo. 
Although these vascular cells are not as ubiquitous in gingival tissue as fibroblasts, their 
location provides the first access to infiltrating immune cells and they may be among the 
earliest cells in the inflammatory cascade to start producing PGE2.  
 
The infiltration of inflammatory cells into the tissue is one of the hallmarks of gingival 
inflammation. The production of PGE2 has been reported in inflammatory cells, such as 
monocytes,237,238 lymphocytes239 and PMNs,240 but mast cells have been poorly studied in 
regard to the expression of PGE synthases and PGE2 production. These cells were therefore 
included in the in vitro studies for the cellular regulation of PGE2 and PGE2-synthesising 
enzymes. Cultured mast cells produced low basal levels of PGE2 and neither TNFα nor IL-
1β treatment affected the PGE2 production or the expression of PGE synthases or COX-2. 
However, mast cell numbers have been shown to be increased in inflamed gingival 
tissue,241,242 suggesting that the basal PGE2 production of these cells may still contribute to 
some degree to the increased PGE2 levels in inflamed gingival tissue through an additive 
effect. To our knowledge, there are a very limited number of studies investigating the 
expression of PGE2-synthesising enzymes or PGE2 production in mast cells; however, 
increased COX-2 expression and PGE2 production has been demonstrated in response to 
antigen stimulation and to the PLA2 activator melittin, respectively.243,244 Among the cells 
included in Study I, more likely contributors to inflammation-induced PGE2 in 
periodontitis are the resident gingival fibroblasts and smooth muscle cells and possibly also 
endothelial cells. However, apart from the gingival fibroblasts, the cells used in our in vitro 
studies are not primary cells isolated from the human gingiva. The results should therefore 
only be taken as indications of possible in vivo mechanisms and our data warrant further 
confirmation also in cells isolated from periodontitis-affected gingival tissue.  
In order more closely to mimic the in vivo situation, we used an in vitro model of 
inflammation in which cells were also co-cultured with lymphocytes. Co-culture of the 
cells with lymphocytes up-regulated mPGES-1 and COX-2 expression in parallel with 
increased PGE2 production in fibroblasts and smooth muscle cells. One explanation for 
this up-regulation is the release of pro-inflammatory cytokines such as IL-1β from the 
lymphocytes,245 stimulating the expression of PGE2-producing enzymes and thereby 
resulting in increased PGE2 production. The results relating to COX-2 up-regulation by 
lymphocytes in gingival fibroblasts are in line with previous results published by our 
group.246 Collectively, these novel results represent a first step in the process of revealing 
the cellular source and mechanism behind increased PGE2 in periodontitis. One possible 
scenario for the contribution of different cell types to inflammation-induced PGE2 
production in gingival connective tissue is depicted in Figure 12.  
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The role of mPGES-1 in cytokine-induced PGE2 production 
(Studies I and II) 
The results obtained from Study I indicated that gingival fibroblasts play an important role 
in inflammation-induced PGE2 production. In the light of this, we are now going to delve 
more deeply into the regulation of PGE2 production in these cells. The PGE synthase 
isoform mPGES-1 is generally considered to be the most inducible, inflammation-related 
enzyme of the three.247,248 To further clarify the role of mPGES-1 in inflammation-induced 
PGE2 synthesis, we used mPGES-1 null gingival fibroblasts derived from mPGES-1 
knock-out mice.249 These cells, isolated here for the first time, demonstrated markedly 
reduced PGE2 production compared with cells from wild-type mice after treatment with 
TNFα (Study I). This indicates that the enzyme mPGES-1 is responsible for a large part of 
the cytokine-induced PGE2 production. The small increase in PGE2 production observed 
in TNFα-stimulated mPGES-1 null gingival fibroblasts may be due to the up-regulation 
of the upstream enzyme COX-2, together with the constitutively expressed mPGES-2 and 
cPGES. The impaired PGE2 response demonstrated by our results is similar to data 
reported for mouse mPGES-1 null macrophages stimulated with LPS.250  
 
Notably, it has been suggested that the second, glutathione-independent, membrane-
associated PGE synthase, mPGES-2, may take over inflammation-induced PGE2 synthesis 
in the event of a non-functional mPGES-1 enzyme.183 To elucidate the hypothesis that 
mPGES-2 and/or cPGES may substitute for mPGES-1 in gingival fibroblasts, we 
investigated the possible up-regulation of mPGES-2 and cPGES, when mPGES-1 was 
knocked down by siRNA or inhibited using molecular inhibitors (Study II). Although the 
silencing of mPGES-1 using siRNA knocked down both TNFα- and IL-1β-stimulated 
mPGES-1 protein expression (39-77% and 54-79% knock-down respectively), no increase 
in mPGES-2 or cPGES expression was observed. The expression of the upstream COX-2 
enzyme was likewise unaffected, suggesting that neither mPGES-2, cPGES nor COX-2 
compensates for the down-regulated mPGES-1 expression. In spite of mPGES-1 knock-
down, the production of PGE2 was not affected. One explanation for this could be an 
alternative pathway for PGE2 synthesis, involving the downstream prostaglandin PGF2α, 
since the levels of PGF2α were increased by anti-mPGES-1 siRNA treatment. The 
prostaglandin PGF2α can be synthesised from PGE2 or directly from PGH2, by distinct 
enzymes.103 It is also possible for PGF2α to be converted to PGE2 by the enzyme PGE 9-
ketoreductase103 and thereby bypass the PGE synthases in PGE2 production. The total 
release of AA, the intermediary for the synthesis of all prostanoids and leukotrienes (see 
Figure 4, page 8), was unaffected by mPGES-1 knock-down. It is possible that, when 
mPGES-1 is knocked down by siRNA, the COX-2 derived PGH2 may be shunted towards 
PGF2α, which can in turn be converted to PGE2 and thereby contribute to PGE2 synthesis. 
This putative mechanism may partly explain the unaffected PGE2 levels. Another possible 
reason for the unaffected PGE2 production could be that the amount of cytokine-
stimulated mPGES-1 that remains after knock-down (21-61% in our experiments) is 
enough to catalyse the conversion of all available COX-2-derived PGH2 to PGE2. In effect, 
this indicates that COX-2 is the rate-limiting enzyme in this setting. The hypothesis that 
COX-2 is the rate-limiting enzyme in the synthesis of PGE2 has been put forward in 
several publications.251-253 However, it has also been suggested that all three enzyme groups 
involved in PGE2 biosynthesis can be rate-limiting,169 and it is possible that, in case of a 
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more efficient knock-down of mPGES-1, this enzyme would become rate-limiting instead 
of COX-2.  
To corroborate the siRNA results, the mPGES-1 inhibitor MK-886 was also used, 
resulting in effects similar to those obtained from mPGES-1 siRNA experiments: MK-886 
reduced mPGES-1 expression without affecting mPGES-2, cPGES, COX-2 or PGE2 
production. In addition, the anti-inflammatory glucocorticoid dexamethasone, which is 
known to have a broad anti-inflammatory effect,254 inhibited mPGES-1 and COX-2 
expression, as well as PGE2 production, without affecting mPGES-2 or cPGES expression.  
 
Our results from the mPGES-1 knock-down experiments in Study II may suggest that 
PGE2 production is more closely correlated to COX-2 expression than to mPGES-1 
expression in gingival fibroblasts. However, the results from the mPGES-1 null fibroblasts 
in Study I show that the total abrogation of mPGES-1 expression does indeed dramatically 
reduce inflammation-induced PGE2 production. Furthermore, the current knowledge of 
the side-effects of specific and non-specific COX-2 inhibitors152,255 used to inhibit 
inflammation-induced PGE2 production turns the spotlight on the PGE synthases. Taken 
together, this motivates further investigations into the endogenous regulation of mPGES-1 
expression.  
 
Signal transduction pathways of cytokine-induced mPGES-1 
expression in gingival fibroblasts (Studies III and IV) 
In Study I, we showed that fibroblasts may play a central role in producing inflammation-
induced PGE2 in gingival tissue. In Studies I and II, we further demonstrated that the most 
important of the three PGE synthases in this regard is mPGES-1, which, together with the 
upstream enzyme COX-2, is responsible for the increased production of PGE2 when 
stimulated with TNFα or IL-1β. The next step was to investigate the intracellular 
signalling pathways that mediate the cytokine-induced up-regulation of mPGES-1 
expression. For this reason, in Studies III and IV, the intracellular regulation of cytokine-
induced mPGES-1 expression was studied in gingival fibroblasts. Inhibitors and 
stimulators of diverse signal transduction pathways were used in Study III to explore the 
complex network of interacting pathways involved in increased mPGES-1 expression.  
To obtain a broader view of regulated signalling pathways in TNFα-stimulated gingival 
fibroblasts, a global gene expression profile was established in Study IV. Enrichment 
analysis of the vast amount of gene expression data led to the further investigation of 
signalling pathways NF-κB and JNK, using specific inhibitors and phosphorylation-
specific immunoassays. The results of Studies III and IV indicated that the JNK and NF-
κB pathways are involved in the signal transduction of cytokine-induced mPGES-1 
expression in gingival fibroblasts. In Study III, the signalling pathways PKC, tyrosine 
kinase and p38 MAP kinase were ruled out as being involved in the signal transduction 
leading to increased mPGES-1 production. However, all three of these pathways were 
shown to be involved in COX-2 regulation, together with the NF-κB and JNK pathways. 
These results of Studies III and IV are summarised and illustrated in Figure 13. Although 
the JNK and NF-κB pathways are involved in both mPGES-1 and COX-2 up-regulation, 
the differences relating to PKC, tyrosine kinase and p38 MAP kinase indicate a lack of 
strict co-regulation of mPGES-1 and COX-2 in gingival fibroblasts. Bearing in mind the 
differential regulation of these enzymes by TNFα in endothelial cells (Study I), mPGES-1 
and COX-2 regulation might be uncoupled in several cell types, including the endothelial 
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cells and gingival fibroblasts investigated in this work. A lack of co-regulation between 
mPGES-1 and COX-2 has also been reported in LPS-stimulated rat microglia, further 
supporting this suggestion.194  
Our novel finding that JNK is involved in TNFα-induced mPGES-1 expression is in 
line with results for IL-1β-stimulated cells, such as cardiac fibroblasts and A549 human 
lung epithelial cells.160,195 Additionally, JNK has been implicated in the chronic 
inflammatory conditions rheumatoid arthritis and inflammatory bowel disease.256,257 The 
results presented here indicate that this pathway may also be important in periodontitis, 
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perhaps even as a possible therapeutic target for chronic inflammation, as suggested for 
rheumatoid arthritis based on the results of rodent models.258  
Our finding that the NF-κB pathway is involved in TNFα-stimulated mPGES-1 
expression is in line with reports on IL-β-stimulated A549 cells and LPS-stimulated 
macrophages.172,199 The glucocorticoid dexamethasone, which is known to act through the 
suppression of NF- B and/or the transcription factor Activator Protein-1,259 inhibited 
cytokine-induced mPGES-1 expression in gingival fibroblasts, further supporting a role for 
NF-κB in mPGES-1 regulation. Notably, it has been suggested that the inhibitory effects 
on mPGES-1 exhibited by anti-inflammatory natural products urolithin-A (from 
metabolised pomegranate) and curcumin (from the spice turmeric) are partly mediated 
through the inhibition of the JNK and NF-κB pathways.195,260  
The transcription factor Egr-1 has been shown to be involved in the regulation of 
mPGES-1 expression in cell types including HeLa cells, murine osteoblastic cells and 
murine macrophages.198-200 Although we found Egr-1 expressed in gingival fibroblasts, the 
Egr-1 stimulator phorbol-12-myristate-13-acetate (PMA)261 did not increase mPGES-1 
expression. The possible involvement of Egr-1 in cytokine-induced mPGES-1 expression 
in gingival fibroblasts therefore merits further study.  
The mPGES-1 promoter contains regulatory elements including activator protein-1, 
glucocorticoid receptor (GR) and early growth response-1 (Egr-1) binding sites.196,197 
Moreover, the transcription factors Egr-1 and NF-κB have been shown to be involved in 
the regulation of mPGES-1 expression in different cell types including HeLa cells, 
pulmonary A549 cells, murine osteoblastic cells and murine macrophages.172,198-200 In 
gingival fibroblasts, we have previously reported that the inflammatory mediators IL-1β 
and TNFα induce the expression of mPGES-1 in parallel with PGE2 production and that 
the glucocorticoid dexamethasone inhibits the expression of mPGES-1.157  
 
Regulation of mPGES-1 by components of the PGE2 
biosynthetic pathway (Study III)  
In Studies III and IV we investigated the signal transduction pathways involved in the 
cytokine-induced mPGES-1 expression and PGE2 production in gingival fibroblasts. Apart 
from signal transduction pathways, a co-ordinated induction of PGE2 synthesis might also 
include inter-regulation between different components of the PGE2 biosynthetic pathway. 
For this reason, we also investigated whether mPGES-1 and COX-2 expression was 
affected by the downstream prostaglandins or the upstream prostaglandin precursors. We 
found that the treatment of gingival fibroblasts with the end product PGE2 or the 
downstream prostaglandin PGF2α increased the expression of mPGES-1 and COX-2, 
suggesting a positive feedback loop in prostaglandin synthesis. In accordance with our 
results, positive feedback regulation of mPGES-1 by exogenous PGE2 has been 
demonstrated in synovial fibroblasts,262 although there are, to our knowledge, no published 
data demonstrating positive feedback by PGF2α.  
The suggested anti-inflammatory prostaglandin 15-deoxy-∆12,14-prostaglandin J2 
(15d-PGJ2) reduced mPGES-1 expression in gingival fibroblasts. The inhibition of 
mPGES-1 expression by 15d-PGJ2 has also been demonstrated in synovial fibroblasts, 
Chinese hamster ovary cells and rat chondrocytes.159,263-265 Since 15d-PGJ2 is the 
endogenous ligand of the transcription factor peroxisome proliferator-activated receptor-γ 
(PPAR-γ),266 the effect on mPGES-1 expression may be mediated through PPAR-γ 
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signalling. Notably, a PPAR-γ-independent pathway for the inhibition of mPGES-1 
expression has been demonstrated in rat chondrocytes, where it was instead proposed that 
15d-PGJ2 inhibits the NF-κB pathway.265 In contrast to its effect on mPGES-1, 15d-PGJ2 
increased COX-2 expression and PGE2 production in gingival fibroblasts, further 
emphasising the un-co-ordinated regulation of mPGES-1 and COX-2. 
Regarding the upstream precursors of PGE2, we showed that the addition of exogenous 
AA, i.e. an increased amount of substrate, enhanced mPGES-1 and COX-2 expression in 
gingival fibroblasts. In accordance with this finding, the chemical inhibition of the enzyme 
PLA2, which catalyses the formation of AA, reduced cytokine-induced mPGES-1 
expression in the cells. These findings indicate that PLA2 is involved in regulating mPGES-
1 expression in gingival fibroblasts. However, the stimulatory effect of exogenous AA on 
the expression of mPGES-1 and COX-2 might also be mediated by an increased amount 
of PGE2 and PGF2α synthesis due to increased substrate availability. The effects of 
prostaglandins and prostaglandin precursors on mPGES-1 and COX-2 expression in 
cytokine-stimulated gingival fibroblasts are illustrated in Figure 14. The stimulatory effect 
of AA, PGE2 and PGF2α on mPGES-1 and COX-2 expression might be involved in 
causing a co-ordinated up-regulation of the enzymes of the PGE2 biosynthetic pathway in 
inflammation. Furthermore, the positive feedback loop involving PGE2 and PGF2α could 
contribute to the self-perpetuation of the local inflammatory reaction. 
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Main findings 
 
• The PGE synthases mPGES-1, mPGES-2 and cPGES, as well as COX-2, are expressed 
in inflamed gingival tissue from patients with periodontitis. In the gingival connective 
tissue, fibroblasts, endothelial cells, smooth muscle cells and inflammatory cells express 
PGE synthases.  
 
• Cultured gingival fibroblasts, human airway smooth muscle (HASM) cells, human 
umbilical vein endothelial cells (HUVECs) and mast cells express mPGES-1, mPGES-
2 and cPGES, as well as COX-2 and consequently produce PGE2. The inflammatory 
cytokines TNFα and IL-1β stimulate the expression of mPGES-1 and COX-2 in 
gingival fibroblasts and HASM cells, accompanied by increased PGE2 production. In 
HUVECs, TNFα increases COX-2 expression and PGE2 production but not mPGES-
1 expression. In mast cells, expression of PGE2-synthesising enzymes and PGE2 
production are not affected by TNFα or IL-1β. 
 
• Inhibition of mPGES-1 expression by siRNA does not affect the expression of 
mPGES-2 and cPGES, indicating that of the three PGE synthase isoforms, mPGES-1 
is the most important enzyme in cytokine-induced PGE2 synthesis in gingival 
fibroblasts.  
 
• In gingival fibroblasts the up-regulation of mPGES-1 and COX-2 expression by 
TNFα involves the signal transduction pathways NF-κB and JNK, and their up-
regulation by IL-1β involves NF-κB.  
 
• In contrast to mPGES-1, cytokine-stimulated COX-2 expression is regulated by PKC, 
tyrosine kinase and p38 MAP kinase, which suggests a lack of co-regulation of these 
two enzymes in gingival fibroblasts. 
 
• The prostaglandins PGE2 and PGF2α have a stimulatory effect on mPGES-1 and 
COX-2 expression, whereas 15d-PGJ2 down-regulates mPGES-1 expression but up-
regulates COX-2 expression.  
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Concluding remarks 
 
The inflammatory mediator PGE2 is involved in the pathogenesis of periodontitis. The 
terminal enzymes in PGE2 biosynthesis, the PGE synthases, are currently in the focus of 
research and are regarded as possible therapeutic targets in chronic inflammatory 
conditions. We demonstrate that all three PGE synthases are expressed in gingival tissue 
from patients with periodontitis. Furthermore, we show that the isoenzyme mPGES-1 is 
the most essential of the PGE synthases in inflammation-induced PGE2 production in 
gingival fibroblasts. This indicates mPGES-1 as an interesting object of research when it 
comes to understanding and possibly also helping to control chronic inflammation in 
periodontal tissue.  
Our findings that the increased mPGES-1 expression in cytokine-stimulated gingival 
fibroblasts involves the signalling pathways JNK and NF-κB but not PKC, tyrosine kinase 
or p38 MAP kinase provide new insights into mPGES-1 regulation in gingival 
inflammation. We also show that the prostaglandins PGE2 and PGF2α may be involved in 
a positive feedback loop which enhances mPGES-1 expression, a mechanism which may 
contribute to the self-perpetuation of the local inflammatory reaction.  
 Our results suggest that the inflammation-induced production of PGE2 by gingival 
fibroblasts is mediated by the increased expression of mPGES-1 and COX-2 and may 
possibly contribute to sustaining the chronic inflammation in periodontitis-affected 
gingival tissue. However, future studies investigating the effect of mPGES-1 inhibition in 
vivo and continuing to explore its regulation in vitro would be of great importance in order 
to further elucidate the role of the PGE synthases in periodontitis. 
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